MCL‐R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R‐CHOP / R‐HAD) AND a RITUXIMAB‐LENALIDOMIDE MAINTENANCE. (June 2017)

• Record Type: Journal Article
• Authors: Ribrag, V.; Feugier, P.; Doorduijn, J.; Delfau‐Larue, M.; Hermine, O.; Kluin‐Nelemans, H.; Dasilva, M.; Lopez‐Hernandez, A.; Walewski, J.; Szymczyk, M.; Pott, C.; Homburg, C.; Van der Velden, V.; Gameiro, P.; Garcia‐Sanz, R.; Ladetto, M.; van Krieken, H.; Cabeçadas, J.; Rymkiewicz, G.; Klapper, W.; Hoster, E.; Le Gouill, S.; Dreyling, M.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 421
• Page End: 421
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2440_3
• Languages: English
• ISSNs: 0278-0232